Silence Therapeutics plc
SLNCF
$2.00
$0.2514.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -95.57% | 14.04% | -58.30% | -65.38% | 15.04% |
| Total Depreciation and Amortization | -6.41% | -1.99% | -4.01% | -3.31% | -2.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 54.74% | -70.13% | 76.27% | 19.38% | -46.19% |
| Change in Net Operating Assets | 130.76% | -279.99% | -907.02% | 24.55% | -124.85% |
| Cash from Operations | 7.94% | -32.69% | -147.85% | -46.03% | -39.06% |
| Capital Expenditure | 73.93% | 21.48% | -61.38% | -900.00% | -288.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -120.35% | 180.36% | 28.51% | 47.34% | -212.80% |
| Cash from Investing | -118.48% | 180.09% | 28.11% | 46.68% | -214.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.99% | -99.99% | -94.96% | -94.28% | 416.18% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.99% | -100.05% | -95.13% | -94.49% | 347.18% |
| Foreign Exchange rate Adjustments | 225.00% | -76.99% | -74.33% | -77.44% | -92.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -309.46% | -107.87% | -193.06% | -189.57% | 1,567.12% |